Ep. 186 Blue Light Cystoscopy: Improving Bladder Cancer Detection with Dr. Suzanne Merrill

1097.267 - 1127.686 Dr. Suzanne Merrill

And as you mentioned, in our superficial bladder cancer, the mixed-grade heterogeneity is up to 30%. And so it's just very important to be able to ensure that we're capturing heterogeneity if you will, the truth about what is in a patient's bladder. Because, for example, with our intermediate risk category of the AUA, that contains patients that are low-grade, okay, as well as high-grade patients.